Identification

Name
Pipecuronium
Accession Number
DB01338
Type
Small Molecule
Groups
Approved
Description

Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.

Structure
Thumb
Synonyms
  • Pipecurium
  • Pipecuronium
Product Ingredients
IngredientUNIICASInChI Key
Pipecuronium bromideR6ZTY81RE152212-02-9TXWBOBJCRVVBJF-YTGGZNJNSA-L
International/Other Brands
Arduan
Categories
UNII
1N3O74HM92
CAS number
68399-58-6
Weight
Average: 602.8912
Monoisotopic: 602.477106492
Chemical Formula
C35H62N4O4
InChI Key
OWWLUIWOFHMHOQ-XGHATYIMSA-N
InChI
InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
IUPAC Name
4-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-13-(4,4-dimethylpiperazin-4-ium-1-yl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-4-yl]-1,1-dimethylpiperazin-1-ium
SMILES
[H][[email protected]@]12C[[email protected]@H]([[email protected]](OC(C)=O)[[email protected]@]1(C)CC[[email protected]@]1([H])[[email protected]@]2([H])CC[[email protected]@]2([H])C[[email protected]](OC(C)=O)[[email protected]](C[[email protected]]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1

Pharmacology

Indication

Used as a muscle relaxant during anesthesia and surgical procedures.

Structured Indications
Not Available
Pharmacodynamics

Pipecuronium is a nondepolarizing neuromuscular blocking agent. Neuromuscular blocking agents produce skeletal muscle paralysis by blocking neural transmission at the myoneural junction. The paralysis is selective initially and usually appears in the following muscles consecutively: levator muscles of eyelids, muscles of mastication, limb muscles, abdominal muscles, muscles of the glottis, and finally, the intercostal muscles and the diaphragm. Neuromuscular blocking agents have no clinically significant effect on consciousness or the pain threshold.

Mechanism of action

Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AcetyldigitoxinPipecuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinPipecuronium may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclarubicinAclarubicin may increase the respiratory depressant activities of Pipecuronium.Investigational
AclidiniumPipecuronium may increase the anticholinergic activities of Aclidinium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ambenonium.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pipecuronium.Approved
annamycinannamycin may increase the respiratory depressant activities of Pipecuronium.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Pipecuronium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
AtracuriumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pipecuronium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pipecuronium.Approved, Vet Approved
BekanamycinBekanamycin may increase the respiratory depressant activities of Pipecuronium.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pipecuronium.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pipecuronium.Approved
BezitramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pipecuronium.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Pipecuronium.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
Botulinum Toxin Type BPipecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Scopolamine butylbromide.Approved, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Pipecuronium.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Pipecuronium.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Chlorphenoxamine.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Pipecuronium.Approved
CimetropiumPipecuronium may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
ClindamycinClindamycin may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
CoumaphosThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Pipecuronium.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pipecuronium.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational, Vet Approved
CymarinPipecuronium may increase the arrhythmogenic activities of Cymarin.Experimental
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pipecuronium.Approved, Investigational
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Pipecuronium.Approved
DecamethoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Pipecuronium.Approved
DeslanosidePipecuronium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipecuronium.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pipecuronium.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dezocine.Approved, Investigational
DibekacinDibekacin may increase the respiratory depressant activities of Pipecuronium.Experimental
DichlorvosThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pipecuronium.Approved
DigitoxinPipecuronium may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinPipecuronium may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Pipecuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Pipecuronium.Investigational, Vet Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Donepezil.Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pipecuronium is combined with DPDPE.Experimental
DronabinolPipecuronium may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Edrophonium.Approved
EluxadolinePipecuronium may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Emepronium.Experimental
EpirubicinEpirubicin may increase the respiratory depressant activities of Pipecuronium.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Pipecuronium.Approved
EtanautineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pipecuronium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fesoterodine.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Pipecuronium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pipecuronium.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Pipecuronium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Pipecuronium.Experimental
GitoformatePipecuronium may increase the arrhythmogenic activities of Gitoformate.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Glucagon recombinant.Approved
GlycopyrroniumPipecuronium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GPX-150GPX-150 may increase the respiratory depressant activities of Pipecuronium.Investigational
HeroinThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pipecuronium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pipecuronium.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Pipecuronium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pipecuronium.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Pipecuronium.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Pipecuronium.Approved
INNO-206INNO-206 may increase the respiratory depressant activities of Pipecuronium.Investigational
IpidacrineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pipecuronium.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Pipecuronium.Experimental
IsoflurophateThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Pipecuronium.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ketobemidone.Approved, Investigational
Lanatoside CPipecuronium may increase the arrhythmogenic activities of Lanatoside C.Experimental
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levorphanol.Approved
LincomycinLincomycin may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
LithiumLithium may increase the neuromuscular blocking activities of Pipecuronium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Lofentanil.Illicit
Magnesium HydroxideMagnesium Hydroxide may increase the neuromuscular blocking activities of Pipecuronium.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Pipecuronium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Pipecuronium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
MalathionThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipecuronium.Approved
MefloquineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pipecuronium.Approved, Investigational
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Pipecuronium.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methylscopolamine bromide.Approved
MetildigoxinPipecuronium may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Pipecuronium.Approved
MetrizamideMetrizamide may increase the respiratory depressant activities of Pipecuronium.Approved
MianserinMianserin may increase the anticholinergic activities of Pipecuronium.Approved, Investigational
MicronomicinMicronomicin may increase the respiratory depressant activities of Pipecuronium.Experimental
MinaprineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Morphine.Approved, Investigational
NabilonePipecuronium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Nalbuphine.Approved
NeamineNeamine may increase the respiratory depressant activities of Pipecuronium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Normethadone.Approved, Illicit
OleandrinPipecuronium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OpiumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pipecuronium.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Otilonium.Experimental, Investigational
OuabainPipecuronium may increase the arrhythmogenic activities of Ouabain.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pipecuronium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pipecuronium.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pipecuronium.Approved
ParaoxonThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Paraoxon.Experimental
ParomomycinParomomycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pipecuronium.Approved
PeruvosidePipecuronium may increase the arrhythmogenic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Pipecuronium.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Physostigmine.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Pipecuronium.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pipecuronium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Pipecuronium.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Piritramide.Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Pipecuronium.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Pipecuronium.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Pipecuronium.Approved
Potassium ChloridePipecuronium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Pipecuronium.Approved, Investigational
ProcainamideProcainamide may increase the neuromuscular blocking activities of Pipecuronium.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pipecuronium.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pipecuronium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Propiverine.Approved, Investigational
ProscillaridinPipecuronium may increase the arrhythmogenic activities of Proscillaridin.Experimental
PuromycinPuromycin may increase the respiratory depressant activities of Pipecuronium.Experimental
PyridostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Pipecuronium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Pipecuronium.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Pipecuronium.Approved
RamosetronPipecuronium may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
RivastigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Rivastigmine.Approved, Investigational
SabarubicinSabarubicin may increase the respiratory depressant activities of Pipecuronium.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipecuronium.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Pipecuronium.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Pipecuronium.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Solifenacin.Approved
SP1049CSP1049C may increase the respiratory depressant activities of Pipecuronium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Pipecuronium.Approved
SufentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pipecuronium.Approved, Investigational
TacrineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tilidine.Experimental
TiotropiumPipecuronium may increase the anticholinergic activities of Tiotropium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pipecuronium.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
TramadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Pipecuronium.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pipecuronium.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pipecuronium.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pipecuronium.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pipecuronium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pipecuronium.Approved
UmeclidiniumPipecuronium may increase the anticholinergic activities of Umeclidinium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Pipecuronium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Pipecuronium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Vecuronium.Approved
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the respiratory depressant activities of Pipecuronium.Investigational
ZorubicinZorubicin may increase the respiratory depressant activities of Pipecuronium.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15431
KEGG Compound
C07554
PubChem Compound
50192
PubChem Substance
46508493
ChemSpider
45517
ChEBI
8230
ChEMBL
CHEMBL1201206
Therapeutic Targets Database
DAP000353
PharmGKB
PA164764567
Wikipedia
Pipecuronium
ATC Codes
M03AC06 — Pipecuronium bromide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.5e-05 mg/mLALOGPS
logP-1.4ALOGPS
logP-5.3ChemAxon
logS-6.8ALOGPS
pKa (Strongest Basic)5.31ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area59.08 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity193.04 m3·mol-1ChemAxon
Polarizability72.22 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8906
Blood Brain Barrier+0.6351
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.8501
P-glycoprotein inhibitor IInhibitor0.7487
P-glycoprotein inhibitor IIInhibitor0.5983
Renal organic cation transporterNon-inhibitor0.7112
CYP450 2C9 substrateNon-substrate0.8587
CYP450 2D6 substrateNon-substrate0.7823
CYP450 3A4 substrateSubstrate0.7542
CYP450 1A2 substrateNon-inhibitor0.9065
CYP450 2C9 inhibitorNon-inhibitor0.9152
CYP450 2D6 inhibitorNon-inhibitor0.9059
CYP450 2C19 inhibitorNon-inhibitor0.8819
CYP450 3A4 inhibitorNon-inhibitor0.8232
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9438
Ames testNon AMES toxic0.752
CarcinogenicityNon-carcinogens0.9083
BiodegradationNot ready biodegradable0.9272
Rat acute toxicity2.6004 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9193
hERG inhibition (predictor II)Non-inhibitor0.7647
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androstane steroids / N-methylpiperazines / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic salts
show 4 more
Substituents
Steroid ester / Androstane-skeleton / N-methylpiperazine / N-alkylpiperazine / 1,4-diazinane / Dicarboxylic acid or derivatives / Piperazine / Tetraalkylammonium salt / Quaternary ammonium salt / Amino acid or derivatives
show 18 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
steroid ester (CHEBI:8230)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786]
  3. Kiss JP, Windisch K, Balla A, Sershen H, Lajtha A: Dual effect of DMPP on the resting release of noradrenaline from rat hippocampal slices. Brain Res Bull. 1997;43(3):257-62. [PubMed:9227834]
  4. Torocsik A, Oberfrank F, Sershen H, Lajtha A, Nemesy K, Vizi ES: Characterization of somatodendritic neuronal nicotinic receptors located on the myenteric plexus. Eur J Pharmacol. 1991 Sep 24;202(3):297-302. [PubMed:1748153]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786]
  2. Zappi L, Song P, Nicosia S, Nicosia F, Rehder K: Do pipecuronium and rocuronium affect human bronchial smooth muscle? Anesthesiology. 1999 Dec;91(6):1616-21. [PubMed:10598601]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Simon G, Biro K, Karpati E, Tuba Z: The effect of the steroid muscle relaxant pipecurium bromide on the acetylcholinesterase activity of red blood cells in vitro. Arzneimittelforschung. 1980;30(2a):360-3. [PubMed:6248079]

Drug created on June 30, 2007 12:08 / Updated on December 01, 2017 17:14